KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Long-Term Investments (2018 - 2025)

Vir Biotechnology's Long-Term Investments history spans 8 years, with the latest figure at $314.6 million for Q4 2025.

  • On a quarterly basis, Long-Term Investments rose 65.55% to $314.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $314.6 million, a 65.55% increase, with the full-year FY2025 number at $314.6 million, up 65.55% from a year prior.
  • Long-Term Investments hit $314.6 million in Q4 2025 for Vir Biotechnology, up from $304.2 million in the prior quarter.
  • Over the last five years, Long-Term Investments for VIR hit a ceiling of $359.7 million in Q1 2024 and a floor of $5.7 million in Q2 2021.
  • Historically, Long-Term Investments has averaged $163.2 million across 5 years, with a median of $147.6 million in 2023.
  • The widest YoY moves for Long-Term Investments: up 1612.02% in 2022, down 88.12% in 2022.
  • Tracing VIR's Long-Term Investments over 5 years: stood at $201.4 million in 2021, then crashed by 88.12% to $23.9 million in 2022, then soared by 339.98% to $105.3 million in 2023, then skyrocketed by 80.49% to $190.0 million in 2024, then soared by 65.55% to $314.6 million in 2025.
  • Business Quant data shows Long-Term Investments for VIR at $314.6 million in Q4 2025, $304.2 million in Q3 2025, and $286.1 million in Q2 2025.